arrow
D

David Cameron

University of Edinburgh
H指数:108
被引数:6.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02

Tucatinib和trastuzumab emtansine用于既往治疗过的HER2阳性局部晚期和转移性乳腺癌患者:随机III期试验HER2CLIMB-02的主要分析

2025-11-170
OAAI
The Breast International Group (BIG) Patient Partnership: Embedding Meaningful Patient Involvement in the Design and Conduct of Breast Cancer Clinical Research

乳腺癌国际组织(BIG)患者伙伴关系:将有意义的患者参与嵌入乳腺癌临床研究的设计与实施

2025-11-100
OAAI
Ten-Year Survival after Postmastectomy Chest-Wall Irradiation in Breast Cancer
2025-11-064
PRE
Tailoring Treatment to Cancer Risk and Patient Preference: The 2025 St Gallen International Breast Cancer Consensus Statement on Individualizing Therapy for Patients With Early Breast Cancer

根据癌症风险和患者偏好调整治疗:2025年圣加仑国际早期乳腺癌共识声明,关于为早期乳腺癌患者个体化治疗。

2025-10-080
OAAI
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial

曲妥珠单抗德鲁替康在HER2低表达转移性乳腺癌中的应用:DESTINY-Breast04随机三期试验的长期生存分析

2025-10-080
OAAI
Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients

预测年轻乳腺癌患者接受化疗和抗HER2治疗后卵巢功能丧失

2025-09-013
OAAI
Association Between Daily Timing of Everolimus and Survival in High-Risk HR+/HER2− Early Breast Cancer: A Sub-Analysis of the UCBG-UNIRAD Trial

依维莫司每日用药时间与高风险HR+/HER2-早期乳腺癌患者生存的关系:UCBG-UNIRAD试验的亚组分析

2025-08-240
PRE
An international Phase IV field study - psychometric properties of the updated module on assessing quality of life of patients with breast cancer EORTC QLQ-BR42

国际IV期实地研究-评估乳腺癌EORTC QLQ-BR42患者生活质量的更新模块的心理计量学特性

BREAST
IF7.9
2025-04-010
OAAI
A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer
2025-02-130
OA
ELEGANT: Elacestrant vs Standard ET in Women and Men With Node-positive, ER+, HER2-Early Breast Cancer (eBC) With High Risk of Recurrence - A Global, Multicenter, Randomized, Open- label Phase 3 Study

ELEGANT研究:Elacestrant与标准ET治疗在淋巴结阳性、ER阳性、HER2阴性早期乳腺癌(eBC)伴高风险复发女性和男性患者中的比较——一项全球、多中心、随机、开放标签III期研究

BREAST
IF7.9
2025-02-010
OAAI
Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]
2024-11-010
PRE
Validation of a breast cancer assay for radiotherapy omission: an individual participant data meta-analysis
2024-10-180
OAAI
Exploratory biomarker analysis of trastuzumab deruxtecan versus treatment of physician's choice in HER2-low, hormone receptorepositive metastatic breast cancer in DESTINY-Breast04

DESTINY-Breast04研究中,曲妥珠单抗德鲁替康与医生选择治疗方案在HER2低表达、激素受体阳性转移性乳腺癌中的探索性生物标志物分析

2024-09-010
PRE
Tailoring neo/adjuvant systemic therapy in breast cancer: The advent of a personalized approach-The Breast-Gynecological and Immuno-Oncology International Cancer Conference (BGICC) consensus and recommendations

定制乳腺癌的新/辅助系统治疗: 个性化方法的出现-乳腺妇科和免疫肿瘤学国际癌症会议 (BGICC) 共识和建议

CANCER
IF5.1
2024-07-100
PRE
Association between endocrine adjuvant therapy intake timing and disease-free survival in patients with high-risk early breast cancer: results of a sub-study of the UCBG- UNIRAD trial
2024-06-010
OAAI
Mammographic surveillance in early breast cancer patients aged 50 years or over: results of the Mammo-50 non-inferiority trial of annual versus less frequent mammography
2024-05-020
PRE